GSK · Pharma and healthcare · one day
GSK (GSK): news on Sunday 25 October 2026
News from the 24 hours to Sunday morning, 25 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was split between positive trial data for Jemperli and mo-rez in ovarian cancer, and a $2.2B Zantac legal charge alongside R&D setbacks. The clinical news leans positive, but the legal costs temper the overall tone.
What drove it
- Jemperli and mo-rez trial data
- Zantac legal charge
- Hutchmed licensing deal
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Mon 19 Oct | +8.5 | 7 |
| Tue 20 Oct | +8.3 | 37 |
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
4 stories · 6 headlines · strongest first
Pharma and healthcare on 25 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK shares ovarian cancer data on mo-rez at ESMO +6.72 headlines today · 4 in all · At ESMO26, GSK has shared data on mo-rez in ovarian cancer. | ||
| +8.3 | Growing evidence for mo-rez in ovarian cancer. | |
| +6.7 | Mo-Rez ovarian data reported, with share price mention. | |
| GSK faces $2.2bn Zantac charge before 28 October results −7.12 headlines today · Pieces discuss GSK's $2.2bn legal charge and R&D setbacks ahead of Oct. 28. | ||
| −7.5 | Legal charges and R&D setbacks weigh on outlook. | |
| −6.7 | $2.2B Zantac charge, partly offset by speciality medicines bet. | |
| GSK reports positive interim Azur-1 Jemperli results +10.01 headline today · GSK says interim Phase II Azur-1 results for Jemperli monotherapy are positive. | ||
| +10.0 | Positive interim phase II results for Jemperli monotherapy. | |
| HUTCHMED licensing deal with GSK closes +5.81 headline today · 12 in all, since 15 October · HUTCHMED closes its GSK licensing deal. | ||
| +3.3 | GSK licensing deal with Hutchmed closed; valuation focus is on Hutchmed.} | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.